Morgan Stanley
NVCT icon

Morgan Stanley’s Nuvectis Pharma NVCT Stock Holding History

Morgan Stanley’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$174K Sell
22,568
-5,443
-19% -$46.6K ﹤0.01% 5929
2025
Q4 		$211K Buy
28,011
+9,494
+51% +$61.9K ﹤0.01% 5910
2025
Q3 		$111K Sell
18,517
-6,176
-25% -$42.5K ﹤0.01% 6107
2025
Q2 		$184K Buy
24,693
+17,716
+254% +$161K ﹤0.01% 5887
2025
Q1 		$68.2K Buy
6,977
+4,658
+201% +$33.5K ﹤0.01% 6167
2024
Q4 		$12.5K Sell
2,319
-29
-1% -$182 ﹤0.01% 6725
2024
Q3 		$14.8K Sell
2,348
-7,850
-77% -$51.7K ﹤0.01% 6601
2024
Q2 		$64.6K Sell
10,198
-30,993
-75% -$211K ﹤0.01% 6099
2024
Q1 		$338K Sell
41,191
-4,639
-10% -$39.4K ﹤0.01% 5506
2023
Q4 		$382K Buy
45,830
+42,351
+1,217% +$378K ﹤0.01% 5720
2023
Q3 		$44.8K Sell
3,479
-1,624
-32% -$23.5K ﹤0.01% 6210
2023
Q2 		$81.5K Buy
5,103
+1,988
+64% +$31.7K ﹤0.01% 6034
2023
Q1 		$40.8K Buy
3,115
+2,814
+935% +$28.5K ﹤0.01% 6354
2022
Q4 		$2.26K Buy
301
+100
+50% +$716 ﹤0.01% 7341
2022
Q3 		$1K Buy
201
+1
+0.5% +$9 ﹤0.01% 7584
2022
Q2 		$2K Buy
+200
New +$2.47K ﹤0.01% 7601

Other funds holding NVCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $165M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Morgan Stanley's NVCT Position: Q1 2026 in Review

Morgan Stanley reduced its Nuvectis Pharma (NVCT) stake by 19% in Q1 2026, selling an estimated $46.6K and leaving 22,568 shares worth $174K. The position accounts for ﹤0.01% of the portfolio, ranked #5929.

Morgan Stanley first reported a position in NVCT in Q2 2022 and has held it in 16 quarters since. The position peaked at $382K in Q4 2023. 62 funds tracked by Wall St. Rank hold NVCT as of Q1 2026.

  • Morgan Stanley held 22,568 shares of Nuvectis Pharma worth $174K as of Q1 2026.
  • Morgan Stanley sold 5,443 Nuvectis Pharma shares in Q1 2026, an estimated $46.6K.
  • Nuvectis Pharma made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #5929 holding.
  • Morgan Stanley first reported a position in Nuvectis Pharma in Q2 2022 and has held it in 16 quarters since.
  • Morgan Stanley's Nuvectis Pharma position peaked at $382K in Q4 2023.
  • 62 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.